CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands

Positive
AI Analysis

Summary

ReCode Therapeutics announced a CEO transition following achievement of clinical validation earlier in 2026, with new leadership to advance its cystic fibrosis and primary ciliary dyskinesia programs.

Importance:3/10
Sentiment:
0.30
leadership changecystic fibrosisprimary ciliary dyskinesiaclinical validation

Read the original article

Published by BioSpace on September 23, 2026 4:18 AM

Read Original